'Regeneus Ltd (ASX: RGS), a clinical-stage regenerative medicine company, today announced that the European Patent Office has decided to grant a patent covering the use of the company’s stem cell secretions technology for the topical treatment of acne.
.....The company is exploring partnering options for the development and commercialisation of the secretions technology.
Skin conditions and wound healing are one of the most promising and near term areas for cell-based regenerative medicine products. With few treatment innovations or improvements in the treatment of acne over the last 10 years, the demand for new improved acne treatments is high.'
